|
|
|
| Expression and Clinical Significance of PD-1 and PD-L1 in Laryngeal Carcinoma |
| FAN Zhuang-zhuang, CUI Ying |
| Postgraduate Training Base of Fushun Central Hospital, Jinzhou Medical University, Fushun 121000, China |
|
|
|
|
Abstract 【Objective】 To investigate the expression and clinical significance of programmed death protein-1 (PD-1) and its ligand (PD-L1) in laryngeal carcinoma. 【Methods】Immunohistochemical SP method was used to detect the expression of PD-1 and PD-L1 in 60 cases of laryngeal squamous cell carcinoma and 33 cases of adjacent tissues, and the relationship between their expression and clinicopathological features and prognosis of laryngeal cancer patients was analyzed. 【Results】 PD-1 and The positive expression rate of PD-L1 was significantly higher than that of adjacent tissues (P<0.05). The positive expression of PD-1 and PD-L1 were related to regional lymph node metastasis, depth and scope of invasion and clinical stage (all P<0.05). The positive expression of PD-L1 was also related to the degree of tumor differentiation (P<0.05). Logrank test showed that there was no significant difference in the mean survival time between PD-1 negative and positive patients(χ2 = 3.065,P=0.089); There was significant difference in the mean survival time between patients with negative and positive expression of PD-L1(χ2=9.002,P=0.003). Cox multivariate analysis showed that PD-L1 was an independent factor affecting the poor prognosis of patients with laryngeal cancer (HR=0.135, 95%CI:0.024~0.756,P=0.023). 【Conclusion】 The positive expression rate of PD-1 and PD-L1 in laryngeal cancer is significantly increased, which is related to the occurrence and development of tumor, and the positive expression of PD-L1 is related to the poor prognosis of patients after operation.
|
|
Received: 30 August 2021
|
|
|
|
|
|
[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2018[J].CA Cancer J Clin,2018 ,68(1):7-30.
[2] CROCI D O, SALATINO M. Tumor immune escape mechanisms that operate during metastasis[J].Curr Pharm Biotechnol,2011,12(11):1923-1936.
[3] CRAMER J D, BURTNESS B, FERRIS R L. Immunotherapy for head and neck cancer: Recent advances and future directions[J].Oral Oncol,2019,99:104460.
[4] CHA J H, CHAN L C, LI C W, et al. Mechanisms controlling PD-L1 expression in cancer[J].Mol Cell,2019 ,76(3):359-370.
[5] HAN M, WANG W, WANG L, et al. Expression of eukaryotic initiation factor 4 E in hypopharyngeal carcinoma[J].J Int Med Res,2014,42(4):976-983.
[6] HAN Y, LIU D, LI L. PD-1/PD-L1 pathway: current researches in cancer[J].Am J Cancer Res,2020,10(3):727-742.
[7] 吴进锋,何毅辉.B7-H3和PD-L1在肾细胞癌组织中的表达及临床意义[J].福建医药杂志,2020,42(2):16-20.
[8] AI L, XU A, XU J. Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond[J].Adv Exp Med Biol,2020,1248:33-59.
[9] 张再兴,周尚清.PD-1、PD-L1在喉癌中的表达及临床意义[J].重庆医学,2018,47(5):635-637.
[10] MÜLLER T, BRAUN M, DIETRICH D, et al. PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma[J].Oncotarget,2017 ,8(32):52889-52900. |
|
|
|
2022, Vol. 39 
